Aller au contenu principal

Billets de Michelle Dawson

Billet publié sur Twitter/X le 13/04/2014 03:41

Twitter/X Essai clinique clinicaltrials.gov Extrait cité dans le billet Question posée par Dawson dans le billet Lien intégré au billet Termes sur l’autisme

Liens cités structurés

1 ressource citée

Essai clinique Récupéré Publication clinicaltrials.gov

University of Colorado, Denver (2015). Phase I Nicotinic Agonist Treatment Trial for Autism. ClinicalTrials.gov. University of Colorado, Denver.

Date de publication
2015
Identifiant
NCT02111551
Auteurs
University of Colorado, Denver
Source
ClinicalTrials.gov
Type de référence
clinical_trial
Éditeur
University of Colorado, Denver
Source de métadonnées
clinicaltrials.gov

Résumé

This study plans to learn more about whether a nicotine-like investigational new drug, DMXB-A \[3-(2,4-dimethoxybenzylidene) anabaseine\] may have positive effects on mental focus and may help us to find new types of treatment for autism spectrum disorder. Subjects will come in for a screening visit and three more drug visits. There will be at least one week between each drug visit to allow the drug to be eliminated from your system completely. During each drug visit subjects will receive either a placebo (a capsule that looks like medicine but is not real), 75 mg of DMXB-A, or 150 mg of DMXB-A. During the drug day vital signs and well being will be monitored by the study physician. Subjects will complete some paper and pencil tasks to test memory, attention, speed, and problem solving, some rating scales and questionnaires, and the study team will record brain wave patterns with an electroencephalogram (EEG).